Granted Patent
B2
US 12,295,952 · App. 18/155,483 · Granted May 13, 2025
Methods of treating heart failure with cardiac sarcomere activators
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Provided herein are methods of treating a subject with heart failure, comprising administering to the subject an initial dose of a cardiac sarcomere activator (CSA) for an initial time period, and subsequently administering to the subject a dose of the CSA based on the subject's plasma concentration of the CSA at the end of the initial time period.
Claims (46)
1. A method of determining a treatment regimen for a subject with heart failure (HF), comprising
(a) administering to the subject an initial dose of a cardiac sarcomere activator (CSA) for an initial time period, wherein the initial dose of the CSA is about 25 mg twice daily,
(b) determining the subject's plasma concentration of the CSA at about 2 weeks after the first administration of the initial dose, and
(c) determining a treatment regimen based on the subject's plasma concentration of the CSA,
wherein the treatment regimen comprises (i) administering to the subject an initial dose of the CSA for an initial time period, wherein the initial dose of the CSA is about 25 mg twice daily; and (ii) subsequently administering to the subject a dose of the CSA for a second time period based on the subject's plasma concentration of the CSA at about 2 weeks after the first administration of the initial dose,
wherein when the subject's plasma concentration of the CSA is less than a threshold concentration of 300 ng/mL, the dose subsequently administered to the subject is greater than the initial dose; and wherein the CSA is omecamtiv mecarbil, or a pharmaceutically acceptable salt thereof.
2. The method of claim 1 , wherein the dose subsequently administered to the subject is a maximum dose.
3. The method of claim 2 , wherein the maximum dose is about 50 mg twice daily.
4. The method of claim 1 , wherein the dose subsequently administered to the subject is about 50 mg twice daily.
5. The method of claim 1 , wherein the dose subsequently administered to the subject is about 37.5 mg twice daily.
6. The method of claim 1 , wherein the dose subsequently administered to the subject is about 25 mg twice daily.
7. The method of claim 1 , wherein the CSA is omecamtiv mecarbil dihydrochloride hydrate.
8. The method of claim 1 , wherein the treatment regimen is effective to achieve a target plasma concentration of about 300 ng/mL to about 750 ng/mL.
9. The method of claim 1 , wherein the initial time period is about 3 weeks.
10. The method of claim 1 , wherein the initial time period is at least about 2 weeks.
11. The method of claim 1 , wherein the initial time period is about 4 weeks.
12. The method of claim 1 , wherein when the subject's plasma concentration of the CSA is greater than or equal to a minimum of a target concentration range, the dose subsequently administered to the subject is the same as the initial dose.
13. The method of claim 12 , wherein the minimum of the target concentration range is 300 ng/mL.
14. The method of claim 1 , wherein the method further comprises administering to the subject a third dose of the CSA for a third time period that follows the second time period based on the subject's second plasma concentration of the CSA.
15. The method of claim 14 , wherein the subject's second plasma concentration of the CSA is measured at about 6 weeks after the first administration of the initial dose.
16. The method of claim 14 , wherein the second time period is at least about 2 weeks.
17. The method of claim 14 , wherein the third dose of the CSA is the same as the second dose when the subject's second plasma concentration of the CSA is less than about 750 ng/ml.
18. The method of claim 14 , wherein the third dose of the CSA is less than the second dose when the subject's second plasma concentration of the CSA is greater than or about 1000 ng/ml.
19. The method of claim 14 , wherein the third dose of the CSA is the same as or less than the second dose when the subject's second plasma concentration of the CSA is greater than or about 750 ng/mL but less than 1000 ng/mL.
20. The method of claim 14 , wherein the third dose is about 25 mg twice daily.
21. The method of claim 14 , wherein the third dose is about 37.5 mg twice daily.
22. The method of claim 14 , wherein the third dose is about 50 mg twice daily.
23. The method of claim 14 , wherein the third dose of the CSA is less than the second dose.
24. The method of claim 14 , wherein the third dose of the CSA is greater than the second dose.
25. The method of claim 14 , wherein the third dose of the CSA is the same as the second dose.
26. The method of claim 1 , wherein the subject has chronic heart failure, or a New York Heart Association Class II or III heart failure.
27. The method of claim 1 , wherein the subject has a left ventricular ejection fraction of about 40% or lower.
28. The method of claim 1 , wherein the subject has a plasma concentration of NT-proBNP of at least about 200 μg/mL.
29. The method of claim 1 , wherein the CSA is administered orally to the subject.
30. A method of determining a treatment regimen for a subject with heart failure (HF), comprising
(a) administering to the subject an initial dose of a cardiac sarcomere activator (CSA) of 25 mg twice daily for an initial time period,
(b) determining the subject's plasma concentration of the CSA at about 2 weeks after the first administration of the initial dose, and
(c) determining a treatment regimen based on the subject's plasma concentration of the CSA,
wherein the treatment regimen comprises (i) administering to the subject an initial dose of the CSA of about 25 mg twice daily for an initial time period; and (ii) subsequently administering to the subject a dose of the CSA for a second time period based on the subject's plasma concentration of the CSA measured at about 2 weeks after the first administration of the initial dose,
wherein the dose subsequently administered to the subject is (ii-a) about 25 mg twice daily, when the subject's plasma concentration of the CSA is greater than or about 300 ng/mL; (ii-b) about 37.5 mg twice daily, when the subject's plasma concentration of the CSA is greater than or about 200 ng/mL but less than 300 ng/mL; or (ii-c) about 50 mg twice daily, when the subject's plasma concentration of the CSA is less than 200 ng/ML; and wherein the CSA is omecamtiv mecarbil, or a pharmaceutically acceptable salt thereof.
31. A method of determining a treatment regimen for a subject with heart failure (HF), comprising
(a) administering to the subject an initial dose of a cardiac sarcomere activator (CSA) of 25 mg twice daily for an initial time period of about 4 weeks,
(b) determining the subject's plasma concentration of the CSA at about 2 weeks after the first administration of the initial dose, and
(c) determining a treatment regimen based on the subject's plasma concentration of the CSA,
wherein the treatment regimen comprises (i) administering to the subject an initial dose of the CSA of about 25 mg twice daily for an initial time period of about 4 weeks; and (ii) subsequently administering to the subject a dose of the CSA for a second time period based on the subject's plasma concentration of the CSA measured at about 2 weeks after the first administration of the initial dose,
wherein the dose subsequently administered to the subject is (ii-a) about 25 mg twice daily, when the subject's plasma concentration of the CSA is greater than or about 300 ng/mL; (ii-b) about 37.5 mg twice daily, when the subject's plasma concentration of the CSA is greater than or about 200 ng/mL but less than 300 ng/mL; or (ii-c) about 50 mg twice daily, when the subject's plasma concentration of the CSA is less than 200 ng/mL; wherein the CSA is omecamtiv mecarbil, or a pharmaceutically acceptable salt thereof; and wherein the CSA is orally administered to the subject.
Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jul 1, 2024
From: HONARPOUR, NARIMON
To: AMGEN INC.
Reel/Frame 067889/0200 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jul 1, 2024
From: MALIK, FADY I.
To: CYTOKINETICS, INC.
Reel/Frame 067889/0356 →
Continuity (3)
Division
16625958
Provisional Application
62527983
· Jun 30, 2017
References Cited (278)
US 4450150A
· Sidman
· 1984
[cited by applicant]
US 6303144B1
· Omura
· 2001
[cited by applicant]
US 7507735B2
· Morgan et al.
· 2009
[cited by applicant]
US 8101617B2
· Morgan et al.
· 2012
[cited by applicant]
US 8110595B2
· Morgan et al.
· 2012
[cited by applicant]
US 8445495B2
· Morgan et al.
· 2013
[cited by applicant]
US 8513257B2
· Morgan et al.
· 2013
[cited by applicant]
US 8871768B2
· Morgan et al.
· 2014
[cited by applicant]
US 8871769B2
· Morgan et al.
· 2014
[cited by applicant]
US 9150564B2
· Morgan et al.
· 2015
[cited by applicant]
US 9643925B2
· Morgan et al.
· 2017
[cited by applicant]
US 9895308B2
· Caldwell
· 2018
[cited by applicant]
US 9951015B2
· Bi et al.
· 2018
[cited by applicant]
US 9988354B2
· Cui et al.
· 2018
[cited by applicant]
US 20070161617A1
· Morgan et al.
· 2007
[cited by applicant]
US 20180312469A1
· Cui et al.
· 2018
[cited by applicant]
US 20200079736A1
· Cui et al.
· 2020
[cited by applicant]
US 20200108076A1
· Scott et al.
· 2020
[cited by applicant]
US 20200331859A1
· Cui et al.
· 2020
[cited by applicant]
US 20210198203A1
· Morgan et al.
· 2021
[cited by applicant]
US 20220324808A1
· Chen et al.
· 2022
[cited by applicant]
US 20230044617A1
· Cui et al.
· 2023
[cited by applicant]
US 20230090391A1
· Bi et al.
· 2023
[cited by applicant]
JP 2020526483A
· 2020
[cited by applicant]
MX 2020000190A
· 2020
[cited by applicant]
WO 9940942A1
· 1999
[cited by applicant]
WO 0032218A1
· 2000
[cited by applicant]
WO 2004033036A2
· 2004
[cited by applicant]
WO 2007133747A2
· 2007
[cited by applicant]
WO 2007141411A1
· 2007
[cited by applicant]
WO 2008130158A1
· 2008
[cited by applicant]
WO 2014152236A1
· 2014
[cited by applicant]
WO 2014152270A1
· 2014
[cited by applicant]
WO 2016210240A1
· 2016
[cited by applicant]
WO 2018144968A1
· 2018
[cited by applicant]
WO 2019006235A1
· 2019
[cited by applicant]
WO 2020011626A1
· 2020
[cited by applicant]
WO 2020014406A1
· 2020
[cited by applicant]
WO 2020020728A1
· 2020
[cited by applicant]
WO 2020180356A1
· 2020
[cited by applicant]
WO 2021053175A1
· 2021
[cited by applicant]
WO 2021053189A1
· 2021
[cited by applicant]
WO 2021070123A1
· 2021
[cited by applicant]
WO 2021070124A1
· 2021
[cited by applicant]
WO 2021092598A1
· 2021
[cited by applicant]
WO 2021123119A1
· 2021
[cited by applicant]
WO 2021136477A1
· 2021
[cited by applicant]
WO 2022103966A1
· 2022
[cited by applicant]
WO 2023205291A2
· 2023
[cited by applicant]
WO 2024081611A1
· 2024
[cited by applicant]
Adjei, A. et al. (Jun. 7, 1990). “Pulmonary Delivery of Peptide Drugs: Effect of Particle Size on Bioavailability of Leuprolide Acetate in Healthy Male Volunteers,” Pharm Res. 7(6):565-569.
[cited by applicant]
Ambrosy, A. P. et al. (Apr. 1, 2014, e-pub. Feb. 5, 2014). “The Global Health Aand Economic Burden of Hospitalizations for Heart Failure: Lessons Learned From Hospitalized Heart Failure Registries,” J Am Coll Cardiol. 6…
[cited by applicant]
Anonymous (Apr. 4, 2016). “Cytokinetics Announces Start of Phase 2 Clinical Trial of Omecamtiv Mecarbil in Japanese Subjects With Heart Failure,” Globe Newswire, 5 pages.
[cited by applicant]
Anonymous (Dec. 1, 2016). “Cytokinetics Announces Start of GALACTIC-HF, A Phase 3 Clinical Trial of Omecamtiv Mecarbil,” Globe Newswire, 6 pages.
[cited by applicant]
Anonymous (Mar. 13, 2015). “Cytokinetics Announces Completion of Enrollment in Cosmic-HF,” Cytokinetics, Inc., 7 pages.
[cited by applicant]
Anonymous (May 1, 2017). “Cytokinetics Announces Results From Dose Escalation Phase of Cosmic-HF Presented at Heart Failure 2017,” Globe Newswire, 6 pages.
[cited by applicant]
Anonymous (Nov. 30, 2016). “The Lancet Publishes Results From Cosmic-HF Trial Showing Omecamtiv Mecarbil Significantly Improved Cardiac Function in Patients With Chronic Heart Failure,” Globe Newswire, 13 pages.
[cited by applicant]
Anonymous (Oct. 27, 2015). “Amgen and Cytokinetics Announce Positive Top-Line Results From Cosmic-HF, A Phase 2 Trial of Omecamtiv Mecarbil in Patients With Chronic Heart Failure,” Globe Newswire, 11 pages.
[cited by applicant]
Anonymous (Sep. 1, 2016). “Cytokinetics and Amgen to Advance Omecamtiv Mecarbil to Phase 3 Clinical Development,” Globe Newswire, 6 pages.
[cited by applicant]
Apple, F. S. et al. (Jul. 2009, e-pub. May 28, 2009). “A New Season for Cardiac Troponin Assays: It's Time to Keep a Scorecard,” Clin Chem. 55(7): 1303-1306.
[cited by applicant]
Bhatia, R. S. et al. (Jul. 20, 2006). “Outcome of Heart Failure With Preserved Ejection Fraction in a Population-Based Study,” N Engl J Med. 355(3):260-269.
[cited by applicant]
Biering-Sorensen, T. et al. (Aug. 2015). “Systolic Ejection Time is an Independent Predictor of Incident Heart Failure in a Community Based Cohort Free of Heart Failure,” Journal of Cardiac Failure 21(8 Supplement):S84,…
[cited by applicant]
Braunwald, E. et al. (Nov. 9, 1967). “Mechanisms of Contraction of The Normal and Failing Heart,” N Engl J Med 277(19):1012-1022.
[cited by applicant]
Bretz, F. et al. (Feb. 15, 2009, e-pub. Dec. 2, 2008). “A Graphical Approach to Sequentially Rejective Multiple Test Procedures,” Stat Med. 28(4):586-604.
[cited by applicant]
Cleland, J. et al. (Aug. 5, 2008). “Predicting the Long-Term Effects of Cardiac Resynchronization Therapy on Mortality From Baseline Variables and the Early Response a Report From the CARE-HF (Cardiac Resynchronization …
[cited by applicant]
Cleland, J. G. F. et al. (Nov. 10, 2009). “Plasma Concentration of Amino-Terminal Pro-Brain Natriuretic Peptide in Chronic Heart Failure: Prediction of Cardiovascular Events and Interaction With the Effects of Rosuvasta…
[cited by applicant]
Cleland, J.G.F. et al. (Aug. 20, 2011). “The Effects of the Cardiac Myosin Activator, Omecamtivmecarbil, on Cardiac Function in Systolic Heart Failure: A Double-Blind, Placebo Controlled, Crossover, Dose-Ranging Phase 2…
[cited by applicant]
Clincialtrials.gov (Jun. 21, 2017). “History of Changes for Study: NCT02929329: Registrational Study With Omecamtiv Mecarbil/AMG 423 to Treat Chronic Heart Failure With Reduced Ejection Fraction (GALACTIC-HF),” 30 pages.
[cited by applicant]
Clincialtrials.gov (May 15, 2017). “History of Changes for Study: NCT02695420: Safety, PK, and Efficacy of Omecamtiv Mercarbil in Japanese Subjects with Heart Failure With Reduced Ejection Fraction,” 6 pages.
[cited by applicant]
Clinicaltrials.gov (May 5, 2016 copy attached; downloaded from the web Nov. 19, 2021). “NCT01786512—COSMIC-HF—Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure,” 10 pages.
[cited by applicant]
Cytokinetics. (2022). “Empowering Muscle Empowering Lives. Sarcomere Directed Therapies,” Cytokinetics 2022, 58 pages.
[cited by applicant]
Dasgupta, A. et al. (2008). “Analytical Techniques for Measuring Concentrations of Therapeutic Drugs in Biological Fluids,” Chapter 3 in Handbook of Drug Monitoring Methods, Humana Press, pp. 67-86.
[cited by applicant]
Deluca, P. P. et al. (1982). “Parenteral Drug-Delivery Systems,” Chapter 8 in Pharmaceutics and Pharmacy Practice, J. B. Lippincott Company, pp. 238-250, 16 pages.
[cited by applicant]
Dickstein, K. et al. (Oct. 2008, e-pub. Sep. 17, 2008). “ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart …
[cited by applicant]
Go, A. S. et al. (Jan. 1, 2013, e-pub. Dec. 12, 2012). “Heart Disease and Stroke Statistics—2013 Update: A Report From the American Heart Association,” Circulation 127(1):e6-e245, 489 pages.
[cited by applicant]
Greenberg, B. H. et al. (Jan. 2015, e-pub. Nov. 11, 2014). “Safety and Tolerability of Omecamtiv Mecarbil During Exercise in Patients With Ischemic Cardiomyopathy and Angina,” JACC Heart Fail. 3(1):22-29.
[cited by applicant]
Greene, S. J. et al. (Apr. 2015, e-pub. Feb. 10, 2015). “The Vulnerable Phase After Hospitalization for Heart Failure,” Nat Rev Cardiol. 12(4):220-229.
[cited by applicant]
Hampton, J. R. et al. (Apr. 5, 1997). “Randomised Study of Effect of Ibopamine on Survival in Patients With Advanced Severe Heart Failure. Second Prospective Randomised Study of Ibopamine on Mortality and Efficacy (PRIM…
[cited by applicant]
Hasenfuss, G. et al. (Aug. 2011, e-pub. Mar. 8, 2011). “Cardiac Inotropes: Current Agents and Future Directions,” Eur Heart J. 32(15):1838-1845.
[cited by applicant]
Haybittle, J.L. (Oct. 1971). “Repeated Assessment of Results in Clinical Trials of Cancer Treatment,” Br J Radiol 44(526):793-797.
[cited by applicant]
Hicks, K. A. et al. (Jul. 28, 2015, e-pub. Dec. 29, 2014). “2014 ACC/AHA Key Data Elements and Definitions for Cardiovascular Endpoint Events in Clinical Trials: A Report of the American College of Cardiology/American H…
[cited by applicant]
Hilfiker-Kleiner, D. et al. (Nov. 7, 2006). “Molecular Mechanisms in Heart Failure: Focus on Cardiac Hypertrophy, Inflammation, Angiogenesis, and Apoptosis,” J Am Coll Cardiol. 48(9 Suppl. A):A56-A66.
[cited by applicant]
International Preliminary Report on Patentability, issued on Dec. 31, 2019, for PCT Application No. PCT/US2018/040181, filed on Jun. 29, 2018, 7 pages.
[cited by applicant]
International Search Report and Written Opinion of the International Searching Authority, mailed Sep. 27, 2018, for PCT Application No. PCT/US2018/040181, filed on Jun. 29, 2018, 10 pages.
[cited by applicant]
Jencks, S. F. et al. (Apr. 2, 2009). “Rehospitalizations Among Patients in the Medicare Fee-for-Service Program,” N Engl J Med. 360(14):1418-1428.
[cited by applicant]
Jessup, M. et al. (May 15, 2003). “Heart Failure,” N Engl J Med. 348(20):2007-2018.
[cited by applicant]
Kang, J. S. et al. (Mar. 2009). “Overview of Therapeutic Drug Monitoring,” Korean J Intern Med. 24(1):1-10.
[cited by applicant]
Kannankeril, P.J. et al. (Nov. 15, 2002). “Usefulness of Troponin I as a Marker of Myocardial Injury After Pediatric Cardiac Catheterization,” Am J Cardiol. 90(10):1128-1132.
[cited by applicant]
Kawashima, Y. et al. (Nov. 1, 1999). “Pulmonary Delivery of Insulin With Nebulized DL-Lactide/Glycolide Copolymer (PLGA) Nanospheres to Prolong Hypoglycemic Effect,” J Control Release 62(1-2):279-287.
[cited by applicant]
Klinkenberg, L. J. J. et al. (May 6, 2014, e-pub. Feb. 26, 2014). “Circulating Cardiac Troponin T Exhibits A Diurnal Rhythm,” J Am Coll Cardiol. 63(17):1788-1795.
[cited by applicant]
Kramer, D.G. et al. (Jul. 27, 2010). “Quantitative Evaluation of Drug or Device Effects on Ventricular Remodeling as Predictors of Therapeutic Effects on Mortality in Patients With Heart Failure and Reduced Ejection Fra…
[cited by applicant]
Krum, H. et al. (Aug. 20, 2011). “Medical Therapy for Chronic Heart Failure,” Lancet. 378(9792):713-721.
[cited by applicant]
Levy, W. C. et al. (Mar. 21, 2006, e-pub. Mar. 13, 2006). “The Seattle Heart Failure Model: Prediction of Survival in Heart Failure,” 113(11):1424-1433.
[cited by applicant]
Liu, L. C. et al. (2016, e-pub. Dec. 19, 2015). “Omecamtiv Mecarbil: A New Cardiac Myosin Activator for the Treatment of Heart Failure,” Expert Opinion on Investigational Drugs 25(1):117-127.
[cited by applicant]
Liu, F. Y. et al. (Feb. 1993). “Pulmonary Delivery of Free and Liposomal Insulin,” Pharm Res. 10(2):228-232.
[cited by applicant]
Lopez-Sendon, J. (Jan. 2011). “The Heart Failure Epidemic,” Medicographia 33(4):363-369.
[cited by applicant]
Malik, F.I. et al. (Mar. 18, 2011). “Cardiac Myosin Activation: A Potential Therapeutic Approach for Systolic Heart Failure,” Science 331(6023):1439-1443, 15 pages.
[cited by applicant]
Malik, F.I. et al. (Oct. 2011, e-pub. May 17, 2011). “Cardiac Myosin Activation Part 1: From Concept to Clinic,” J Mol Cell Cardiol. 51(4):454-461.
[cited by applicant]
McLlvennan, C. K. et al. (Dec. 2014, e-pub. Aug. 20, 2014). “Outcomes in Acute Heart Failure: 30-Day Readmission Versus Death,” Curr Heart Fail Rep. 11(4):445-452.
[cited by applicant]
Mozaffarian, D. et al. (Jul. 24, 2007, e-pub. Jul. 9, 2007). “Prediction of Mode of Death in Heart Failure: the Seattle Heart Failure Model,” Circulation 116(4):392-398.
[cited by applicant]
Nagy, L. et al. (Sep. 2014). “Inotropes and Inodilators for Acute Heart Failure: Sarcomere Active Drugs in Focus,” J Cardiovasc Pharmacol. 64(3):199-208.
[cited by applicant]
NCT02695420—(May 15, 2017). History of Changes of Study: Safety, PK, and Efficacy of omecamtiv mecarbil in Japanese Subjects With Heart Failure With Reduced Ejection Fraction, ClinicalTrials.gov, retrieved from the Inte…
[cited by applicant]
Packer, M. (Jul. 15, 1993). “The Search For The Ideal Positive Inotropic Agent,” N Engl J Med. 329(3):201-202.
[cited by applicant]
Packer, M. et al. (Nov. 21, 1991). “Effect of Oral Milrinone on Mortality in Severe Chronic Heart Failure. The PROMISE Study Research Group,” N Engl J Med. 325(21):1468-1475.
[cited by applicant]
Palaparthy, R.et al. (Mar. 1, 2016, e-pub. Dec. 28, 2015). “Relative Bioavailability, Food, Effect and Safety of the Single-Dose Pharmacokinetics of Omecamtiv Mecarbil Following Administration of Different Modified-Rele…
[cited by applicant]
Peto, R. et al. (Dec. 1976). “Design and Analysis of Randomized Clinical Trials Requiring Prolonged Observation of Each Patient. I. Introduction and Design,” Br J Cancer 34(6):585-612.
[cited by applicant]
Ponikowski, P. et al. (Aug. 2016, e-pub. May 20, 2016). “2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart …
[cited by applicant]
Qian, F. et al. (Jan. 21, 2009, e-pub. Nov. 5, 2008). “Pulmonary Delivery of a GLP-1 Receptor Agonist, BMS-686117,” Int J Pharm 366(1-2):218-220.
[cited by applicant]
Qian, F. et al. (Jun. 5, 2009, e-pub. Mar. 19, 2009). “Sustained Release Subcutaneous Delivery of BMS-686117, a GLP-1 Receptor Peptide Agonist, Via a Zinc Adduct,” Int J Pharm. 374(1-2):46-52.
[cited by applicant]
Rahimi, K. et al. (Oct. 2014, e-pub. Sep. 3, 2014). “Risk Prediction in Patients With Heart Failure: A Systematic Review and Analysis,” JACC Heart Fail 2(5):440-446.
[cited by applicant]
Shave, R. et al. (Jul. 13, 2010). “Exercise-Induced Cardiac Troponin Elevation: Evidence, Mechanisms, and Implications,” J Am Coll Cardiol. 56(3):169-176.
[cited by applicant]
Shen, Y.T. et al. (Jul. 2010). “Improvement of Cardiac Function by a Cardiac Myosin Activator in Conscious Dogs With Systolic Heart Failure,” Circ Heart Fail 3(4):522-527.
[cited by applicant]
Shih, J. H. (Dec. 1995). “Sample Size Calculation for Complex Clinical Trials With Survival Endpoints,” Control Clin Trials. 16(6):395-407.
[cited by applicant]
Solomon, S. D. et al. (Oct. 12, 2004, e-pub. Oct. 4, 2004). “Effect of Candesartan on Cause-Specific Mortality in Heart Failure Patients: The Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidi…
[cited by applicant]
Solomon, S. D. et al. (Sep. 7, 2010, e-pub. Aug. 23, 2010). “Effect of Cardiac Resynchronization Therapy on Reverse Remodeling and Relation to Outcome: Multicenter Automatic Defibrillator Implantation Trial: Cardiac Res…
[cited by applicant]
Steijns, L. S. W. et al. (Jun. 2002). “Evaluation of Fluorescence Polarization Assays for Measuring Valproic Acid, Phenytoin, Carbamazepine and Phenobarbital in Serum,” Ther Drug Monit. 24(3):432-435.
[cited by applicant]
Tacon, C. L. et al. (Mar. 2012, e-pub. Dec. 8, 2011). “Dobutamine for Patients With Severe Heart Failure: A Systematic Review and Meta-Analysis of Randomised Controlled Trials,” Intensive Care Med. 38(3):359-367.
[cited by applicant]
Teerlink, J. R. et al. (Dec. 10, 2016, e-pub. Dec. 1, 2016). “Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF): A Phase 2, Pharmacokinetic, Randomised, Placebo-Controlled Tr…
[cited by applicant]
Teerlink, J.R. et al. (2016). “Online Appendix: Acute Treatment With Omecamtiv Mecarbil to Increase Contractility in Acute Heart Failure: the ATOMIC AHF Study,” J. Am. Coll. Cardiol. 67:1444-1455, Appendix, 16 pages.
[cited by applicant]
Teerlink, J.R. et al. (Aug. 20, 2011). “Dose-Dependent Augmentation of Cardiac Systolic Function With the Selective Cardiac Myosin Activator, Omecamtiv Mecarbil: A First-In-Man Study,” Lancet 378(9792):667-675.
[cited by applicant]
Teerlink, J.R. et al. (Mar. 29, 2016). “Acute Treatment With Omecamtiv Mecarbil to Increase Contractility in Acute Heart Failure: The ATOMIC-AHF Study,” J Am Coll Cardiol 67(12):1444-1455.
[cited by applicant]
Teerlink, J.R. et al. (May 2014). “Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF): Improved Contractility and Evolution of Ventricular Remodelling Through Time,” European …
[cited by applicant]
Thygesen, K. et al. (Oct. 16, 2012, e-pub. Sep. 5, 2012). “Third Universal Definition of Myocardial Infarction,” J Am Coll Cardiol 60(16):1581-1598.
[cited by applicant]
Trissel, L. A. et al. (1986). “Intravenous Infusion Solutions,” ASHP Handbook on Injectable Drugs, 4th ed., pp. 622-630.
[cited by applicant]
U.S. Appl. No. 15/898,303, filed Feb. 16, 2018, by William Brett Caldwell et al. (U.S. Patent Application is not submitted herewith pursuant to the waiver of 37 C.F.R. § 1.98(a)(2)(iii) issued by the Office on Sep. 21, …
[cited by applicant]
U.S. Appl. No. 17/176,003, filed Feb. 15, 2021, by Sheng Cui et al. (U.S. Patent Application is not submitted herewith pursuant to the waiver of 37 C.F.R. § 1.98(a)(2)(iii) issued by the Office on Sep. 21, 2004.).
[cited by applicant]
Vu, T. et al. (Nov. 2015, e-pub. Jul. 14, 2015). “Population Pharmacokinetic-Pharmacodynamic Modeling of Omecamtiv Mecarbil, a Cardiac Myosin Activator, in Healthy Volunteers and Patients With Stable Heart Failure,” J C…
[cited by applicant]
Waldenstrom, A. et al. (Jan. 17, 2014). “Role of Exosomes in Myocardial Remodeling,” Circ Res. 114(2):315-324.
[cited by applicant]
Wang, G-F. et al. (Nov. 2008). “Measurement of Plasma Concentration and Bioavailability of Nolatrexed Dihydrochloride in Mice,” J South Med Univ 28(11):1993-1995, with English Abstract.
[cited by applicant]
Weissler, A. M. et al. (Feb. 1968). “Systolic Time Intervals in Heart Failure in Man,” Circulation 37(2):149-159.
[cited by applicant]
Yancy, C. W. et al. (Oct. 15, 2013, e-pub. Jun. 5, 2013). “2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on …
[cited by applicant]
Yancy, C. W. et al. (Sep. 27, 2016, e-pub. May 20, 2016). “2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure:…
[cited by applicant]
American Heart Association Editorial Staff (Last Reviewed Jun. 7, 2023). “Classes and Stages of Heart Failure,” American Heart Association, Retrieved from Internet: https://www.heart.org/en/health-topics/heart-failure/w…
[cited by applicant]
Berge, S.M. et al. (Jan. 1977). “Pharmaceuticals Salts,” J. Pharmaceutical Sciences 66(1):1-19.
[cited by applicant]
Chen, P-W. et al. (Apr. 1, 2022). “Population Pharmacokinetic Properties of Omecamtiv Mecarbil in Healthy Subjects and Patients With Heart Failure With Reduced Ejection Fraction,” J Cardiovasc Pharmacol. 79(4):539-548.
[cited by applicant]
Hicks, K.A. et al. (Mar. 6, 2018). “2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials,” J Am Coll Cardiol 71(9):1021-1034.
[cited by applicant]
Teerlink, J.R. et al. (Jan. 14, 2021, e-pub. Nov. 13, 2020). “Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure,” N Engl J Med. 384(2):105-116.
[cited by applicant]
U.S. Appl. No. 18/342,387, filed Jun. 27, 2023, by Fady Malik et al. (U.S. Patent Application is not submitted herewith pursuant to the waiver of 37 C.F.R. § 1.98(a)(2)(iii) issued by the Office on Sep. 21, 2004.).
[cited by applicant]
U.S. Appl. No. 18/416,741, filed Jan. 18, 2024, by Henry Morrison et al. (U.S. Patent Application is not submitted herewith pursuant to the waiver of 37 C.F.R. § 1.98(a)(2)(iii) issued by the Office on Sep. 21, 2004.).
[cited by applicant]
U.S. Appl. No. 18/421,849, filed Jan. 24, 2024, by Shang Cui et al. (U.S. Patent Application is not submitted herewith pursuant to the waiver of 37 C.F.R. § 1.98(a)(2)(iii) issued by the Office on Sep. 21, 2004.).
[cited by applicant]
U.S. Appl. No. 18/531,424, filed Dec. 6, 2023, by Mingda Bi et al. (U.S. Patent Application is not submitted herewith pursuant to the waiver of 37 C.F.R. § 1.98(a)(2)(iii) issued by the Office on Sep. 21, 2004.).
[cited by applicant]
U.S. Appl. No. 18/520,156, Nov. 27, 2023, by Shang Cui et al.(U.S. Patent Application is not submitted herewith pursuant to the waiver of 37 C.F.R. § 1.98(a)(2)(iii) issued by the Office on Sep. 21, 2004.).
[cited by applicant]
Ahmad, T. et al. (2019, e-pub. Aug. 13, 2019). “Why Has Positive Inotropy Failed in Chronic Heart Failure? Lessons From Prior Inotrope Trials,” Eur J Heart Fail 21:1064-1078.
[cited by applicant]
Allen, L.A. et al. (Apr. 17, 2012). “Decision Making in Advanced Heart Failure: A Scientific Statement From the American Heart Association,” Circulation 125(5):1928-1952.
[cited by applicant]
Allen, L.A. et al. (Mar. 2014). “Hospital Variation in Intravenous Inotrope Use for Patients Hospitalized With Heart Failure: Insights From Get With the Guidelines,” Circ Heart Fail. 7(2):251-260.
[cited by applicant]
Ammar, K.A. et al. (Mar. 27, 2007). “Prevalence and Prognostic Significance of Heart Failure Stages,” Circulation 115(12):1563-1570.
[cited by applicant]
Benjamini, Y. et al. (1995). “Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing,” Journal of the Royal Statistical Society. Series B Methodological 57(1):289-300.
[cited by applicant]
Biering-Sorensen, T. et al. (Dec. 2020). “Cardiac Myosin Activator Omecamtiv Mecarbil Improves Left Ventricular Myocardial Deformation in Chronic Heart Failure: The COSMIC-HF Trial,” Circ Heart Fail 13(12):e008007, 5 pa…
[cited by applicant]
Biering-Sorensen, T. et al. (Nov. 11, 2019). “The Effect of the Cardiac Myosin Activator, Omecamtiv Mecarbil, on Diastolic Filling and Function in Chronic Systolic Heart Failure (COSMIC-HF)”, Circ. 140(Suppl1): A14405, …
[cited by applicant]
Burnett, J.C. Jr. (Dec. 2019). “Atrial Natriuretic Peptide, Heart Failure and the Heart as an Endocrine Organ,” Clin Chem. 65(12):1602-1603.
[cited by applicant]
Butler, J. et al. (2020, e-pub. Apr. 2, 2020). “Minimal Clinically Important Difference in Quality of Life Scores for Patients With Heart Failure and Reduced Ejection Fraction,” Eur J Heart Fail 22:999-1005.
[cited by applicant]
Butzner, M. et al. (May 2020). “Medical Therapy Side Effects Across Heart Failure Patients With Reduced Ejection Fraction: A Systematic Literature Review”, Value in Health 23(Suppl1): S91, 1 page.
[cited by applicant]
Chen, P. et al. (Sep. 6, 2021). “Model-based Analysis of Omecamtiv Mecarbil Pharmacokinetics Properties,” Presented at 2021 Annual Meeting American College of Clinical Pharmacology, Sep. 13, 2021, Poster 100, Clin Pharm…
[cited by applicant]
Cleland, J.G.F. et al. (2018, e-pub. Oct. 10, 2017). “Beta-Blockers for Heart Failure With Reduced, Mid-Range, and Preserved Ejection Fraction: An Individual Patient-Level Analysis of Double-Blind Randomized Trials,” Eu…
[cited by applicant]
Cohen, S.S. et al. (Oct. 2020). “Characteristics and Outcomes of a Real-world Population with Heart Failure with Reduced Ejection Fraction Representative of Clinical Trial Patients”, J Card. Fail. 26(10S):S82, p. 1.
[cited by applicant]
Comin-Colet, J. et al. (Jul. 2018, e-pub. Feb. 6, 2018). “Efficacy and Safety of Intermittent Intravenous Outpatient Administration of Levosimendan in Patients With Advanced Heart Failure: The LION-HEART Multicentre Ran…
[cited by applicant]
Crespo-Leiro M.G. et al. (2018, e-pub. Jul. 17, 2018). “Advanced Heart Failure: A Position Statement of the Heart Failure Association of the European Society of Cardiology,” European Journal of Heart Failure 20:1505-153…
[cited by applicant]
Cui, D. et al. (Jan. 2021). “Levosimendan Can Improve the Level of B-Type Natriuretic Peptide and the Left Ventricular Ejection Fraction of Patients With Advanced Heart Failure: A Meta-Analysis of Randomized Controlled …
[cited by applicant]
Desai, N.R. et al. (Mar. 8, 2022). “Healthcare Resource Use, Intensity and Costs Among Patients with Heart Failure with Reduced Ejection Fraction Treated with Omecamtiv Mecarbil in GALACTIC-HF”, J. Am. Coll Cardiol. 79(…
[cited by applicant]
Desai, N.R. et al. (Nov. 7, 2022). “Healthcare Resource Use, Early Benefit and Cost for North American Patients With HFrEF Most Likely to Benefit From Omecamtiv Mecarbil”, Circ. 146(Suppl1):Abstract 11481, 2 pages.
[cited by applicant]
Dewan, P. et al. (2020, e-pub. Jun. 15, 2020). Efficacy and Safety of Sodium-Glucose Co-Transporter 2 Inhibition According to Left Ventricular Ejection Fraction in DAPA-HF. Eur J Heart Fail 22:1247-1258.
[cited by applicant]
Docherty, K.F. et al. (Mar. 8, 2022). “The Effect of Omecamtiv Mecarbil in Hospitalized Patients as Compared with Outpatients: a Prespecified Analysis of GALACTIC-HF,” J. Am. Coll. Cardiol. 79(9):310, Abstract, 1 page.
[cited by applicant]
Ezekowitz, J.A. et al. (Nov. 2020). “N-Terminal Pro-B-Type Natriuretic Peptide and Clinical Outcomes: Vericiguat Heart Failure With Reduced Ejection Fraction Study,” JACC Heart Fail 8(11):931-939.
[cited by applicant]
Fang, J.C. et al. (Jun. 2015, e-pub. May 4, 2015). “Advanced (Stage D) Heart Failure: A Statement From the Heart Failure Society of America Guidelines Committee,” Journal of Cardiac Failure 21(6):519-534.
[cited by applicant]
Grodin, J.L. et al. (Mar. 25, 2019). Prognostic Implications of Changes in Amino-Terminal Pro-B-Type Natriuretic Peptide in Acute Decompensated Heart Failure: Insights From ASCEND-HF. J Card Fail. 25(9):703-711. (Accept…
[cited by applicant]
Hardy, R.J. et al. (Mar. 30, 1996). “A Likelihood Approach to Meta-Analysis With Random Effects,” Stat Med 15(6):619-629.
[cited by applicant]
Ibrahim, N.E. et al. (May 2020). “Natriuretic Peptides as Inclusion Criteria in Clinical Trials: A JACC: Heart Failure Position Paper,” JACC Heart Fail. 8(5):347-358.
[cited by applicant]
International Preliminary Report on Patentability mailed on May 16, 2023, for PCT Application No. PCT/US2021/058988, filed on Nov. 11, 2021, 7 pages.
[cited by applicant]
International Search Report and Written Opinion mailed on Feb. 2, 2024, for PCT Application PCT/US2023/076419, filed on Oct. 10, 2023, 14 pages.
[cited by applicant]
International Search Report and Written Opinion mailed on Feb. 4, 2022, for PCT Application No. PCT/US2021/058988, filed on Nov. 11, 2021, 17 pages.
[cited by applicant]
International Search Report and Written Opinion mailed on Jul. 19, 2024, for PCT Application No. PCT/US2024/025668, filed on Apr. 22, 2024, 15 pages.
[cited by applicant]
Kotecha, D. et al. (Dec. 20, 2014). “Efficacy of β Blockers in Patients With Heart Failure Plus Atrial Fibrillation: An Individual-Patient Data Meta-Analysis,” The Lancet 384(9961):2235-2243, 44 pages.
[cited by applicant]
Kristensen, S.L. et al. (Mar. 2019). “N-Terminal Pro-B-Type Natriuretic Peptide Levels for Risk Prediction in Patients With Heart Failure and Preserved Ejection Fraction According to Atrial Fibrillation Status,” Circ He…
[cited by applicant]
Kristensen, S.L. et al. (Oct. 2017). “Prognostic Value of N-Terminal Pro-B-Type Natriuretic Peptide Levels in Heart Failure Patients With and Without Atrial Fibrillation,” Circ Heart Fail. 10(10):e004409, 9 pages.
[cited by applicant]
Lee, D.S. et al. (Sep. 14, 2005). “Risk Treatment Mismatch in the Pharmacotherapy of Heart Failure,” JAMA 294(10):1240-1247.
[cited by applicant]
Loungani, R.S. et al. (Jul. 2020). “Biomarkers in Advanced Heart Failure: Implications for Managing Patients With Mechanical Circulatory Support and Cardiac Transplantation,” Circ Heart Fail. 13(7):e006840, 10 pages.
[cited by applicant]
Mann, D.L. et al. (Oct. 2020). “Sacubitril/Valsartan in Advanced Heart Failure With Reduced Ejection Fraction,” JACC: Heart Failure 8(10):789-799.
[cited by applicant]
McMurray, J.J.V. et al. (Nov. 21, 2019, e-pub. Sep. 19, 2019). “Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction,” N Engl J Med 381(21):1995-2008.
[cited by applicant]
Merck Sharp & Dohme Corp. (Jan. 19, 2021). Verquvo Tablets. Center for Drug Evaluation and Research, Food and Drug Administration. Integrated Review, Application No. 2143770rig1s000, NDA 214377 Vericiguat, 10 pages.
[cited by applicant]
Metra, M. et al. (2007). “Advanced Chronic Heart Failure: A Position Statement From the Study Group on Advanced Heart Failure of the Heart Failure Association of the European Society of Cardiology,” European Journal of …
[cited by applicant]
Metra, M. et al. (2009, e-pub. Aug. 22, 2009). “Effects of Low-Dose Oral Enoximone Administration on Mortality, Morbidity, and Exercise Capacity in Patients With Advanced Heart Failure: The Randomized, Double-Blind, Pla…
[cited by applicant]
Morgan, B. et al. (Aug. 19, 2018). “Discovery and Development of Omecamtiv Mecarbil—a Novel Cardiac Myosin Activator for the Potential Treatment of Systolic Heart Failure,” Abstract, ACS Fall 2018, as posted on https://…
[cited by applicant]
MSD Manual Editorial Staff. “New York Heart Association (NYHA Classification of Heart Failure,” XP93180881, MSD Manual Professional Version, Retrieved from Internet: https://www.msdmanuals.com/professional/multimedia/ta…
[cited by applicant]
Mueller, C. et al. (Jun. 2019). “Heart Failure Association of the European Society of Cardiology Practical Guidance on the Use of Natriuretic Peptide Concentrations,” Eur J Heart Fail. 21(6):715-731.
[cited by applicant]
Najjar, E. et al. (Jun. 2018, e-pub. Feb. 22, 2018). “Haemodynamic Effects of Levosimendan in Advanced but Stable Chronic Heart Failure,” ESC Heart Fail. 5(3):302-308.
[cited by applicant]
Nizamic, T. et al. (Sep. 2018). “Ambulatory Inotrope Infusions in Advanced Heart Failure: A Systematic Review and Meta-Analysis,” JACC Heart failure 6(9):757-767.
[cited by applicant]
Pabon, M.A.P. et al (Oct. 30, 2022). “Sex Differences in Heart Failure with Reduced Ejection Fraction in the GALACTIC-HF Trial,” Circ. 146(Suppl1): Abstract 13640, 1 page.
[cited by applicant]
Packer, M. (Oct. 8, 2020, e-pub. Aug. 28, 2020). “Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure,” N Engl J Med 383(15):1413-1424.
[cited by applicant]
Packer, M. et al. (May 23, 1996). “The Effect of Carvedilol on Morbidity and Mortality in Patients with Chronic Heart Failure,” N Engl J Med. 334(21):1349-1355.
[cited by applicant]
Pitt, B. et al. (Sep. 2, 1999). “The Effect of Spironolactone on Morbidity and Mortality in Patients With Severe Heart Failure,” N Engl J Med. 341(10):709-717.
[cited by applicant]
Planelles-Herrero, V.J. et al. (2017, e-pub. Aug. 4, 2017). “Mechanistic and Structural Basis for Activation of Cardiac Myosin Force Production by Omecamtiv Mecarbil,” Nat Commun 8(190):1-10.
[cited by applicant]
Psotka, M.A. et al. (2017). “Direct Myosin Activation by Omecamtiv Mecarbil for Heart Failure with Reduced Ejection Fraction,” Handb Exp Pharmacol 243:465-490, 35 pages.
[cited by applicant]
Psotka, M.A. et al. (May 14, 2019). “Cardiac Calcitropes, Myotropes, and Mitotropes,” J Am Coll Cardiol 73(18):2345-2353.
[cited by applicant]
Riskin, D. et al. (Nov. 12, 2020). “Enabling Advanced Real-world Evidence in Heart Failure: A Pilot Study Defining Preferred Approaches to Electronic Health Record Data Use”, Circ. 142(Suppl3): Abstract 13797, 2 pages.
[cited by applicant]
Rorth, R. et al. (Feb. 2020). “Comparison of BNP and NT-proBNP in Patients With Heart Failure and Reduced Ejection Fraction,” Circ Heart Fail. 13(2):e006541, 10 pages.
[cited by applicant]
Solomon, S.D. et al. (Dec. 13, 2005). “Influence of Ejection Fraction on Cardiovascular Outcomes in a Broad Spectrum of Heart Failure Patients,” Circulation 112(24):3738-3744, 11 pages.
[cited by applicant]
Solomon, S.D. et al. (Feb. 4, 2020). “Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure,” Circulation 141:352-361.
[cited by applicant]
Solomon, S.D. et al. (Mar. 2016). “Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: The Prospective Comparison of ARNI with ACEI t…
[cited by applicant]
Stewart, G.C. et al. (Nov. 9, 2016). “INTERMACS (Interagency Registry for Mechanically Assisted Circulatory Support) Profiling Identifies Ambulatory Patients at High Risk on Medical Therapy After Hospitalizations for He…
[cited by applicant]
Tahhan, A.S. et al. (Oct. 2018, e-pub. Aug. 22, 2018). “Enrollment of Older Patients, Women, and Racial and Ethnic Minorities in Contemporary Heart Failure Clinical Trials: A Systematic Review,” JAMA Cardiol 3(10):1011-…
[cited by applicant]
Teerlink, J.R. et al. (Apr. 2020). “Omecamtiv Mecarbil in Chronic Heart Failure With Reduced Ejection Fraction: Rationale and Design of GALACTIC-HF,” JACC Heart Fail 8(4):329-340.
[cited by applicant]
Teerlink, J.R. et al. (Dec. 21/28, 2021). “The Effect of Omecamtiv Mecarbil on Stroke in Patients With Heart Failure and Reduced Ejection Fraction in GALACTIC-HF”, Circ. 144(25): Abstract 16605, 1 page.
[cited by applicant]
Teerlink, J.R. et al. (Jan. 14, 2021, e-pub. Nov. 13, 2020). “Supplementary Appendix. Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure,” N Engl J Med. 384(2):1-55.
[cited by applicant]
Teerlink, J.R. et al. (Jul. 13, 2021, e-pub. May 17, 2021). “Effect of Ejection Fraction on Clinical Outcomes in Patients Treated With Omecamtiv Mecarbil in GALACTIC-HF,” Journal of the American College of Cardiology 78…
[cited by applicant]
Teerlink, J.R. et al. (Mar. 12, 2019). “Effect of Omecamtiv Mecarbil in Patients with Atrial Fibrillation and Heart Failure with Reduced Ejection Fraction: Results from COSMIC-HF,” JACC 73(9):691.
[cited by applicant]
Teerlink, J.R. et al. (Nov. 2020, e-pub. Oct. 27, 2020). “Omecamtiv Mecarbil in Chronic Heart Failure With Reduced Ejection Fraction: GALACTIC-HF Baseline Characteristics and Comparison With Contemporary Clinical Trials…
[cited by applicant]
Trivedi, A. et al. (Sep. 6, 2021). “Effect of Varying Degrees of Hepatic Impairment on the Pharmacokinetics of Omecamtiv Mecarbil,” Presented at 2021 Annual Meeting American College of Clinical Pharmacology, Sep. 13, 20…
[cited by applicant]
Trivedi, A. et al. (Sep. 6, 2021). “Effect of Varying Degrees of Renal Impairment on the Pharmacokinetics of Omecamtiv Mecarbil,” Presented at 2021 Annual Meeting American College of Clinical Pharmacology, Sep. 13, 2021…
[cited by applicant]
Trivedi, A. et al. (Sep. 6, 2021). “Omecamtiv Mecarbil Does Not Prolong QTc Intervals at Therapeutic Concentrations,” Presented at 2021 Annual Meeting American College of Clinical Pharmacology, Sep. 13, 2021, Poster 021…
[cited by applicant]
Trivedi, A. et al. (Sep. 6, 2021). “Pharmacokinetic Drug-Drug Interaction Study of Ome-camtiv Mecarbil With MATE1/MATE2-K Substrate Metformin in Healthy Subjects,” Presented at 2021 Annual Meeting American College of Cl…
[cited by applicant]
Trivedi, A. et al. (Sep. 6, 2021). “Pharmacokinetic Drug-Drug Interaction Study of Omecamtiv Mecarbil With Amiodarone in Healthy Subjects,” Presented at 2021 Annual Meeting American College of Clinical Pharmacology, Sep…
[cited by applicant]
Trivedi, A. et al. (Sep. 6, 2021). “Pharmacokinetic Drug-Drug Interaction Study of Omecamtiv Mecarbil with Breast Cancer Resistance Protein Substrate, Rosuvastatin, in Healthy Subjects,” Presented at 2021 Annual Meeting…
[cited by applicant]
Trivedi, A. et al. (Sep. 6, 2021). “Pharmacokinetic Drug-Drug Interaction Study of Omecamtiv Mecarbil With Midazolam, a CYP3A4 Sensitive Index Substrate, in Healthy Subjects,” Presented at 2021 Annual Meeting American C…
[cited by applicant]
Trivedi, A. et al. (Sep. 6, 2021). “Pharmacokinetic Drug-Drug Interaction Study of Omecamtiv Mecarbil with P-glycoprotein Substrate Digoxin in Healthy Subjects,” Presented at 2021 Annual Meeting American College of Clin…
[cited by applicant]
Trivedi, A. et al. (Sep. 6, 2021). “Pharmacokinetic Drug-Drug Interaction Study of Omecamtiv Mecarbil With Proton Pump Inhibitor, Omeprazole in Healthy Subjects,” Presented at 2021 Annual Meeting American College of Cli…
[cited by applicant]
Trivedi, A. et al. (Sep. 6, 2021). “Pharmacokinetics, Disposition & Biotransformation of [14C]-Omecamtiv Mecarbil in Healthy Male Subjects After a Single Intravenous or Oral Dose,” Presented at 2021 Annual Meeting Ameri…
[cited by applicant]
Trivedi, A. et al. (Sep. 6, 2021). “Relative Bioavailability of Omecamtiv Mecarbil Pediatric Minitablet Formulations in Healthy Subjects,” Presented at 2021 Annual Meeting American College of Clinical Pharmacology, Sep.…
[cited by applicant]
Trivedi, A. et al. (Sep. 6, 2021). “Switchability & Minimal Effect of Food on Pharmacokinetics of Modified-release Tablet Strengths of Omecamtiv Mecarbil, a Cardiac Myosin Activator,” Presented at 2021 Annual Meeting Am…
[cited by applicant]
Troughton, R.W. et al. (Jun. 14, 2014, e-pub. Mar. 6, 2014). “Effect of B-type Natriuretic Peptide-Guided Treatment of Chronic Heart Failure on Total Mortality and Hospitalization: An Individual Patient Meta-Analysis,” …
[cited by applicant]
U.S. Appl. No. 18/642,005, filed Apr. 22, 2024, by Fady Malik et al. (U.S. Patent Application is not submitted herewith pursuant to the waiver of 37 C.F.R. § 1.98(a)(2)(iii) issued by the Office on Sep. 21, 2004.).
[cited by applicant]
U.S. Appl. No. 18/939,410, filed Nov. 6, 2024, by Elena Brasola et al. (U.S. Patent Application is not submitted herewith pursuant to the waiver of 37 C.F.R. § 1.98(a)(2)(iii) issued by the Office on Sep. 21, 2004.).
[cited by applicant]
Unroe, K.T. et al. (Feb. 14, 2011, e-pub. Oct. 11, 2010). “Resource Use in the Last 6 Months of Life Among Medicare Beneficiaries With Heart Failure, 2000-2007,” Archives of Internal Medicine 171(3):196-203.
[cited by applicant]
Vaduganathan, M. et al. (Jul. 2018). “Natriuretic Peptides as Biomarkers of Treatment Response in Clinical Trials of Heart Failure,” JACC Heart Fail. 6(7):564-569.
[cited by applicant]
Wessler, B.S. et al. (2019, e-pub. Mar. 27, 2019). “Relation Between Therapy-Induced Changes in Natriuretic Peptide Levels and Long-Term Therapeutic Effects on Mortality in Patients With Heart Failure and Reduced Ejecti…
[cited by applicant]
Yancy, C.W. et al. (Oct. 15, 2013). “2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,” …
[cited by applicant]
Zile, M.R. et al. (Dec. 6, 2016). “Prognostic Implications of Changes in N-Terminal Pro-B-Type Natriuretic Peptide in Patients With Heart Failure,” J Am Coll Cardiol. 68(22):2425-2436.
[cited by applicant]
Cited By (2)